First Tracks Biotherapeutics, Inc. (TRAX)
NASDAQ: TRAX · Real-Time Price · USD
35.83
-0.83 (-2.26%)
Sep 24, 2026, 4:00 PM EDT - Market closed
First Tracks Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company, newly formed and well-funded, is advancing a pipeline led by ANB033, a dual-mechanism CD122 antagonist targeting autoimmune diseases, with phase I-B trials in celiac disease and EoE. Data readouts are expected over the next year, with plans for further indication expansion and a focus on differentiation in a competitive landscape.
-
A newly independent biotech with $180 million in cash is advancing a pipeline of antibody therapies for autoimmune diseases, led by ANB033 targeting CD122. Key phase I-B trials in celiac disease and EoE are ongoing, with major data readouts expected in Q4 and mid-2027.